NASDAQ:SANA

Sana Biotechnology (SANA) Stock Forecast, Price & News

$6.70

+0.49 (+7.89%)

(As of 06/8/2023 ET)

Compare

Today's Range: $6.08
▼
$6.82
50-Day Range: $3.11
▼
$7.53
52-Week Range: $2.99
▼
$9.55

Volume: 1.11 million shs
Average Volume: 1.19 million shs
Market Capitalization: $1.28 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Sana Biotechnology MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 49.3% Upside
$10.00 Price Target
Short Interest: Bearish
33.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$2.80 M Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

659th out of 981 stocks

Biological Products, Except Diagnostic Industry

107th out of 163 stocks

3.2

Analyst's Opinion

Consensus Rating
Sana Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Sana Biotechnology has a forecasted upside of 49.3% from its current price of $6.70.
Amount of Analyst Coverage
Sana Biotechnology has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
33.83% of the float of Sana Biotechnology has been sold short.
Short Interest Ratio / Days to Cover
Sana Biotechnology has a short interest ratio ("days to cover") of 21.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Sana Biotechnology has recently increased by 0.04%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Sana Biotechnology does not currently pay a dividend.
Dividend Growth
Sana Biotechnology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SANA.

3.1

News and Social Media Coverage

News Sentiment
Sana Biotechnology has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
Search Interest
16 people have searched for SANA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
3 people have added Sana Biotechnology to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sana Biotechnology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,796,366.00 in company stock.
Percentage Held by Insiders
34.90% of the stock of Sana Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
67.12% of the stock of Sana Biotechnology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Sana Biotechnology are expected to remain at ($1.49) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sana Biotechnology is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sana Biotechnology is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sana Biotechnology has a P/B Ratio of 2.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sana Biotechnology (NASDAQ:SANA) Stock

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Receive SANA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sana Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SANA Stock News Headlines

June 1, 2023 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.6%

May 31, 2023 | finance.yahoo.com

Sana Biotechnology to Present at June 2023 Investor Conferences

June 8, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 30, 2023 | msn.com

Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday

May 29, 2023 | americanbankingnews.com

Ventures Fund V. Gener Flagship Sells 82,000 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) Stock

May 29, 2023 | americanbankingnews.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Major Shareholder Ventures Fund V. Gener Flagship Sells 347,870 Shares

May 26, 2023 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 6.2%

May 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Immunovant (IMVT) and Sana Biotechnology (SANA)

June 8, 2023 | Behind the Markets (Ad)

Why did Biden repeal Trump's Executive Order?!

" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "

May 22, 2023 | finance.yahoo.com

Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data

May 17, 2023 | americanbankingnews.com

Sana Biotechnology Target of Unusually Large Options Trading (NASDAQ:SANA)

May 11, 2023 | msn.com

Unusual Call Option Trade in Sana Biotechnology (SANA) Worth $29.48K

May 11, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Sana Biotechnology, Inc. Decreased by HC Wainwright (NASDAQ:SANA)

May 11, 2023 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Up 8.5%

May 9, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Hold Rating on Sana Biotechnology (SANA)

May 8, 2023 | msn.com

Sana Biotechnology Non-GAAP EPS of -$0.43

May 8, 2023 | finance.yahoo.com

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

May 8, 2023 | finance.yahoo.com

Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional

May 4, 2023 | americanbankingnews.com

Sana Biotechnology, Inc. Forecasted to Post Q1 2023 Earnings of ($0.35) Per Share (NASDAQ:SANA)

May 3, 2023 | finance.yahoo.com

Sana Biotechnology to Present at May 2023 Investor Conferences

May 3, 2023 | finance.yahoo.com

Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade

May 2, 2023 | tmcnet.com

Sana Biotechnology Announces the Acceptance of Six Abstracts

May 2, 2023 | msn.com

HC Wainwright & Co. Initiates Coverage of Sana Biotechnology (SANA) with Neutral Recommendation

May 2, 2023 | msn.com

Sana Biotech initiated Neutral at H.C. Wainwright on valuation

May 2, 2023 | finance.yahoo.com

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Invest In Growth?

May 2, 2023 | finance.yahoo.com

Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

May 2, 2023 | bizjournals.com

Sana fills 2 senior roles as the Seattle biotech shifts focus

See More Headlines

SANA Price History

30 days | 90 days | 365 days | Advanced Chart

SANA Company Calendar

Last Earnings: 3/16/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SANA
CUSIP: N/A
CIK: 1770121
Web: sana.com
Phone: 206-701-7914
Fax: N/A
Employees: 383
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $10.00
High Stock Price Forecast: $13.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +49.3%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.69)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-269,480,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.06%
Return on Assets: -39.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.60
Quick Ratio: 3.60

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.62 per share
Price / Book: 2.56

Miscellaneous

Outstanding Shares: 191,500,000
Free Float: 124,667,000
Market Cap: $1.28 billion
Optionable: Not Optionable
Beta: 0.71

Key Executives

Dr. Steven D. Harr M.D. (Age 53)
Pres, CEO & Director
Comp: $1.19M

Dr. Richard C. Mulligan Ph.D. (Age 68)
Exec. Vice Chairman & Head of SanaX

Mr. Nathan Hardy M.B.A. (Age 47)
Exec. VP & CFO
Comp: $683.49k

Dr. Sunil Agarwal M.D. (Age 53)
Exec. VP, Head of Devel. & Chief Medical Officer
Comp: $728.45k

Brittany Mccleery
Accounting Mang.

Dr. Edward Rebar Ph.D. (Age 55)
Sr. VP & CTO

Mr. Bernard J. Cassidy J.D. (Age 68)
Exec. VP & Gen. Counsel

Ms. Robin Andrulevich (Age 57)
Exec. VP & Chief People Officer

Mr. Paul Brunetta M.D.
Sr. VP and Head of Clinical & Translational Science

Ms. Donna Dambach D.V.M.
Ph.D., Sr. VP & Head of Devel. Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SANA Stock - Frequently Asked Questions

Should I buy or sell Sana Biotechnology stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SANA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SANA, but not buy additional shares or sell existing shares.
View SANA analyst ratings or view top-rated stocks.
What is Sana Biotechnology's stock price forecast for 2023?: 3 Wall Street research analysts have issued 1 year price objectives for Sana Biotechnology's stock. Their SANA share price forecasts range from $6.00 to $13.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 49.3% from the stock's current price.
View analysts price targets for SANA or view top-rated stocks among Wall Street analysts.
How have SANA shares performed in 2023?: Sana Biotechnology's stock was trading at $3.95 at the beginning of 2023. Since then, SANA stock has increased by 69.6% and is now trading at $6.70.
View the best growth stocks for 2023 here.
When is Sana Biotechnology's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our SANA earnings forecast.
How were Sana Biotechnology's earnings last quarter?: Sana Biotechnology, Inc. (NASDAQ:SANA) announced its quarterly earnings results on Thursday, March, 16th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01.
What ETFs hold Sana Biotechnology's stock?: ETFs with the largest weight of Sana Biotechnology (NASDAQ:SANA) stock in their portfolio include SPDR S&P Biotech ETF (XBI), iShares Genomics Immunology and Healthcare ETF (IDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), ProShares Ultra Nasdaq Biotechnology (BIB), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB).

When did Sana Biotechnology IPO?: (SANA) raised $322 million in an IPO on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities served as the underwriters for the IPO.
What is Sana Biotechnology's stock symbol?: Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."
Who are Sana Biotechnology's major shareholders?: Sana Biotechnology's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (5.68%), FMR LLC (4.78%), BlackRock Inc. (4.07%), State Street Corp (2.97%), Price T Rowe Associates Inc. MD (2.36%) and JPMorgan Chase & Co. (1.28%). Insiders that own company stock include Christian Hordo, James J Macdonald, Joshua H Bilenker, Patrick Y Yang and Ventures Fund V Gener Flagship.
View institutional ownership trends.
How do I buy shares of Sana Biotechnology?: Shares of SANA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sana Biotechnology's stock price today?: One share of SANA stock can currently be purchased for approximately $6.70.
How much money does Sana Biotechnology make?: Sana Biotechnology (NASDAQ:SANA) has a market capitalization of $1.28 billion. The company earns $-269,480,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.
How many employees does Sana Biotechnology have?: The company employs 383 workers across the globe.
How can I contact Sana Biotechnology?: Sana Biotechnology's mailing address is 188 EAST BLAINE STREET SUIT 400, SEATTLE WA, 98102. The official website for the company is sana.com. The company can be reached via phone at 206-701-7914 or via email at investor.relations@sana.com.

This page (NASDAQ:SANA) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial